|Trade names||Noristerat, Norigest, others|
|AHFS/Drugs.com||International Drug Names|
|Chemical and physical data|
|Molar mass||410.588 g/mol|
|(what is this?)|
Norethisterone enanthate (NET-EN), also known as norethindrone enanthate, is a form of progestogen-only injectable birth control. It may be used following childbirth, miscarriage, or abortion. The failure rate per year is 2 per 100 women. Each dose lasts two months with up to two doses recommended.
Side effects may include breast pain, headaches, depression, irregular menstrual periods, and pain at the site of injection. Use in those with liver disease or during pregnancy is not recommended. Use appears to be okay during breastfeeding. It does not protect against sexually transmitted infections. Norethisterone enanthate is an ester of norethisterone, by which it works. It works by stopping ovulation.
Norethisterone was patented in 1951 and came into medical use in 1957. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 1.04 to 7.99 USD per 200 mg vial. It has been approved in more than 40 countries including the United Kingdom and some in Europe, Central America, and Africa. It is not available in the United States.
- "Noristerat 200mg, solution for intramuscular injection - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Retrieved 31 December 2016.
- Committee on Contraceptive Development (U.S.) (1 January 1990). Luigi Mastroianni; Peter J. Donaldson; Thomas T. Kane, eds. Developing New Contraceptives: Obstacles and Opportunities. National Academies. pp. 38–. NAP:14119.
- WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 370. ISBN 9789241547659. Retrieved 8 December 2016.
- Wu L, Janagam DR, Mandrell TD, Johnson JR, Lowe TL (2015). "Long-acting injectable hormonal dosage forms for contraception". Pharmaceutical Research. 32 (7): 2180–91. PMID 25899076. doi:10.1007/s11095-015-1686-2.
- Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 478. ISBN 9783527607495.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
- "Norethisterone". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- Amy Whitaker; Melissa Gilliam (27 June 2014). Contraception for Adolescent and Young Adult Women. Springer. p. 96. ISBN 978-1-4614-6579-9.
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 417–. ISBN 978-92-832-1291-1.
Norethisterone and its acetate and enanthate esters are progestogens that have weak estrogenic and androgenic properties.
- Vern L. Bullough (2001). Encyclopedia of Birth Control. ABC-CLIO. pp. 145–. ISBN 978-1-57607-181-6.